建银国际发表报告指,对康方生物(9926.HK)AK112的海外临床试验持更加乐观的态度。2月25日,公司美国合作伙伴Summit Therapeutics宣布,将启动AK112在美国的临床试验。AK112是康方生物已获批的针对肺部相关癌症的双特异性抗体,此次试验将与辉瑞的多种抗体药物偶联物进行联合疗法试验。与早先披露的信息一致,Summit Therapeutics计划发布AK112联合化疗的...
Source Link建银国际发表报告指,对康方生物(9926.HK)AK112的海外临床试验持更加乐观的态度。2月25日,公司美国合作伙伴Summit Therapeutics宣布,将启动AK112在美国的临床试验。AK112是康方生物已获批的针对肺部相关癌症的双特异性抗体,此次试验将与辉瑞的多种抗体药物偶联物进行联合疗法试验。与早先披露的信息一致,Summit Therapeutics计划发布AK112联合化疗的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.